ORKA trades 42.8% below Wall Street's consensus target of $137.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ORKA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 18, 2026, Oruka Therapeutics, Inc. (ORKA) has a Wall Street consensus price target of $137.50, based on estimates from 9 covering analysts. With the stock currently trading at $96.32, this represents a potential upside of +42.8%. The company has a market capitalization of $5.81B.
Analyst price targets range from a low of $120.00 to a high of $180.00, representing a 44% spread in expectations. The median target of $125.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ORKA trades at a trailing P/E of -45.2x. Analysts expect EPS to grow -12.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
REGNRegeneron Pharmaceuticals, Inc. | $98.7B | $957.76 | $904.60 | -5.6% | Buy | 14.1x | 49 |
SANASana Biotechnology, Inc. | $523M | $1.88 | $8.50 | +352.1% | Buy | — | 11 |
ARQTArcutis Biotherapeutics, Inc. | $3.4B | $27.33 | $41.80 | +52.9% | Buy | 66.3x | 12 |
IMVTImmunovant, Inc. | $6.9B | $33.21 | $40.00 | +20.4% | Buy | — | 23 |
ABBVAbbVie Inc. | $517.4B | $292.82 | $308.88 | +5.5% | Buy | 21.0x | 44 |
LLYEli Lilly and Company | $1.3T | $1415.55 | $1445.12 | +2.1% | Buy | 40.1x | 46 |
PFEPfizer Inc. | $162.3B | $28.47 | $31.13 | +9.4% | Hold | 9.5x | 40 |
ALNYAlnylam Pharmaceuticals, Inc. | $20.9B | $156.50 | $330.54 | +111.2% | Buy | 8.5x | 52 |
ROIVRoivant Sciences Ltd. | $28.0B | $38.71 | $49.50 | +27.9% | Buy | — | 16 |
AMGNAmgen Inc. | $247.1B | $457.93 | $415.58 | -9.2% | Buy | 19.5x | 41 |
Quick answers to the most common questions about buying ORKA stock.
The consensus Wall Street price target for ORKA is $137.5, representing 42.8% upside from the current price of $96.32. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ORKA has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $137.5 implies 42.8% upside from current levels.
ORKA's current price is $96.32 with a consensus target of $137.5 (42.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $180 for ORKA, while the most conservative target is $120. The consensus of $137.5 represents the median expectation. These targets typically reflect 12-month expectations.
ORKA is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ORKA stock forecast based on 9 Wall Street analysts shows a consensus price target of $137.5, with estimates ranging from $120 (bear case) to $180 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ORKA, with a "Buy" consensus rating and $137.5 price target (42.8% upside). 9 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ORKA analyst price targets range from $120 to $180, a 44% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $137.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.